Inventor · disambiguated record
Toshihiko Ohtomo
Also filed as: OHTOMO TOSHIHIKO
26 granted patents·14 pending applications·207 citations·filing 1994–2023
95Inventor score
Files withCHUGAI PHARMACEUTICAL CO LTD26ABURATANI HIROYUKI5TSUCHIYA MASAYUKI2CHUGAI SEIYAKU KUBUSHIKI KAISH1Chugai Seiyako Kabushiki Kaisha1
Top patents by PatentIndex Score
40 records- 0192US8586039B2Degraded TPO agonist antibodyTSUCHIYA MASAYUKI·Filed 2011·Granted Nov 19, 2013·20 cites·27 claims
- 0286US6989244B1Method for screening compounds inhibiting signal transduction through inflammatory cytokinesCHUGAI PHARMACEUTICAL CO LTD·Filed 1999·Granted Jan 24, 2006·71 cites·20 claims
- 0383US10782300B2GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapyCHUGAI PHARMACEUTICAL CO LTD·Filed 2013·Granted Sep 22, 2020·4 cites·21 claims
- 0483US8034903B2Degraded TPO agonist antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2001·Granted Oct 11, 2011·8 cites·11 claims
- 0583US7812128B2Gene overexpressed in cancerABURATANI HIROYUKI·Filed 2008·Granted Oct 12, 2010·3 cites·2 claims
- 0681US6551840B2Method of screening TGF-β-inhibiting substancesCHUGAI PHARMACEUTICAL CO LTD·Filed 2002·Granted Apr 22, 2003·16 cites·8 claims
- 0780US11376326B2GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effectiveCHUGAI PHARMACEUTICAL CO LTD·Filed 2016·Granted Jul 5, 2022·2 cites·16 claims
- 0879US11767362B1Methods of treating cancers using PD-1 axis binding antagonists and anti-GPC3 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2017·Granted Sep 26, 2023·2 cites·8 claims
- 0979US6908750B2Gene encoding HM1.24 antigen protein and promoter thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 2003·Granted Jun 21, 2005·4 cites·11 claims
- 1075US6699974B2Reshaped human anti-HM 1.24 antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 1997·Granted Mar 2, 2004·32 cites·9 claims
- 1175US6214973B1Reshaped human antibody to human medulloblastoma cellsCHUGAI PHARMACEUTICAL CO LTD·Filed 1994·Granted Apr 10, 2001·26 cites·18 claims
- 1271US9434775B2Gene overexpressed in cancerABURATANI HIROYUKI·Filed 2009·Granted Sep 6, 2016·0 cites·4 claims
- 1366US7563599B2Reshaped human antibody to human medulloblastoma cellsCHUGAI PHARMACEUTICAL CO LTD·Filed 2004·Granted Jul 21, 2009·0 cites·2 claims
- 1464US2024026006A1Methods of treating cancers using pd-1 axis binding antagonists and anti-gpc3 antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2023·Application pending·0 cites
- 1563US7892543B2Reshaped human anti-HM 1.24 antibodyChugai Seiyako Kabushiki Kaisha·Filed 2002·Granted Feb 22, 2011·3 cites·46 claims
- 1663US2009311718A1Degraded agonist antibodyCHUGAI PHARMACEUTICAL CO LTD·Filed 2009·Application pending·0 cites
- 1763US2007037204A1Gene overexpressed in cancerCHUGAI PHARMACEUTICAL CO LTD·Filed 2006·Application pending·0 cites
- 1861US7338797B2Compositions for isolating a cDNA encoding a membrane-bound proteinCHUGAI PHARMACEUTICAL CO LTD·Filed 2003·Granted Mar 4, 2008·0 cites·20 claims
- 1958US2005019780A1Compositions for isolating a cDNA encoding a membrane-bound proteinCHUGAI SEIYAKU KUBUSHIKI KAISH·Filed 2003·Application pending·0 cites
- 2057US6610485B1Methods for isolating a cDNA encoding a membrane-bound proteinCHUGAI PHARMACEUTICAL CO LTD·Filed 1999·Granted Aug 26, 2003·8 cites·13 claims
- 2156US9376475B2Gene overexpressed in cancerABURATANI HIROYUKI·Filed 2010·Granted Jun 28, 2016·0 cites·10 claims
- 2255US8105799B2Methods of screening compounds inhibiting signal transduction through inflammatory cytokinesTSUCHIYA MASAYUKI·Filed 2008·Granted Jan 31, 2012·0 cites·16 claims
- 2355US2008009038A1Methods for Enhancing Antibody ActivityCHUGAI PHARMACEUTICAL CO LTD·Filed 2004·Application pending·0 cites
- 2454US10451627B2Method for assaying soluble GPC3 proteinCHUGAI PHARMACEUTICAL CO LTD·Filed 2014·Granted Oct 22, 2019·0 cites·6 claims
- 2554US2006040316A1Method for screening compounds inhibiting signal transduction through inflammatory cytokinesCHUGAI PHARMACEUTICAL CO LTD·Filed 2005·Application pending·0 cites
- 2654US2013295096A1Degraded agonist antibodyFUKUSHIMA NAOSHI·Filed 2013·Application pending·0 cites
- 2754US2004258684A1Agonist antibodiesCHUGAI PHARMACEUTICAL CO LTD·Filed 2002·Application pending·0 cites
- 2854US2003023045A1Reshaped human antibody to human medulloblastoma cellsFiled 2000·Application pending·0 cites
- 2953US9644029B2Cancer diagnosis and treatment of cancer using anti-ROBO1 antibodyABURATANI HIROYUKI·Filed 2014·Granted May 9, 2017·0 cites·14 claims
- 3050US2004058393A1Agonist antibodiesFiled 2001·Application pending·0 cites
- 3150US2003162228A1Method of screening TGF-beta-inhibiting substancesCHUGAI PHARMACEUTICAL CO LTD·Filed 2003·Application pending·0 cites
- 3249US7666610B2Expressing transporters on viral envelopesCHUGAI PHARMACEUTICAL CO LTD·Filed 2003·Granted Feb 23, 2010·0 cites·22 claims
- 3348US2020216542A1Dosage regimen for combination therapy using pd-1 axis binding antagonists and gpc3 targeting agentCHUGAI PHARMACEUTICAL CO LTD·Filed 2018·Application pending·0 cites
- 3448US2004242847A1Degraded agonist antibodyFiled 2001·Application pending·0 cites
- 3546US7067297B2Mannosyltransferase polypeptides and polynucleotides encoding them and methods for making and using themCHUGAI PHARMACEUTICAL CO LTD·Filed 2001·Granted Jun 27, 2006·0 cites·8 claims
- 3642US2008153104A1Gene Overexpressed in CancerHIROYUKI ABURANTAI·Filed 2004·Application pending·0 cites
- 3741US8940488B2Cancer diagnosis and treatment of cancer using anti-robo 1 antibodyABURATANI HIROYUKI·Filed 2005·Granted Jan 27, 2015·0 cites·22 claims
- 3840US6613546B1Gene encoding HM1.24 antigen protein and promoter thereofCHUGAI PHARMACEUTICAL CO LTD·Filed 1999·Granted Sep 2, 2003·4 cites·6 claims
- 3937US6451617B1Method of screening TGF-β inhibitory substancesCHUGAI PHARMACEUTICAL CO LTD·Filed 1998·Granted Sep 17, 2002·4 cites·50 claims
- 4032US11760807B2GPC3-targeting drug which is administered to patient responsive to GPC3-targeting drug therapyCHUGAI PHARMACEUTICAL CO LTD·Filed 2015·Granted Sep 19, 2023·0 cites·10 claims
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →